Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market
April 16 2024 - 2:06PM
In October of 2023, the US FDA approved Novartis’ intravenous (IV)
formulation of Cosentyx (secukinumab) for the treatment of
psoriatic arthritis (PsA), ankylosing spondylitis (AS) and
non-radiographic axial spondyloarthritis (nr-axSpA). Approximately
five months post-approval, over one-third of US rheumatologists
(n=104) report prescribing the IV formulation for their patients
with PsA. Furthermore, the vast majority feel the new formulation
of Novartis’ IL-17-inhibitor brings some degree of advance over
existing PsA treatments.
Receptivity to the IV formulation has also resulted in a greater
affinity for the Cosentyx brand overall, specifically in comparison
to long-standing IL-17 rival, Eli Lilly’s Taltz. Indeed, for the
first time in several years, Cosentyx has grown its established
preference lead over Taltz, with respondents pointing to their
overall experience with Novartis’ brand as well as the increased
administration options as reasons behind their growing
preference.
While the approval of the IV formulation of Cosentyx has had
only a minor impact on overall IL-17 share in PsA thus far, future
projections reveal growth of the brand, fueled by both an expanding
user and patient base. However, one aspect that could blunt the
growth of Cosentyx is the pending entry of UCB’s Bimzelx, the
potential first monoclonal antibody that dually inhibits both
IL-17A and IL-17F.
Rheumatologists are highly anticipating the approval of Bimzelx
and are most likely to choose Bimzelx’s dual IL-17A/F pathway as
the most efficacious, particularly when measured directly against
other IL-17s. Furthermore, while previous queries on prescriber
differentiation between the various IL-17 pathways revealed that
most regard them all as a part of the same overall IL-17 mechanism
of action (MOA), a sizeable portion of specialists now believe the
dual inhibition of both IL-17A and IL-17F could be considered a new
MOA, apart from legacy IL-17A alone.
Among all late-stage pipeline PsA assets queried,
rheumatologists were most aware of and familiar with Bimzelx.
Rheumatologists are also most interested in having Bimzelx approved
for PsA, followed closely by BMS’ Sotyktu. Most specialists intend
to trial Bimzelx within six months of availability and the brand’s
uptake is projected to most likely disrupt use of Taltz, Cosentyx
and TNFs.
Spherix will continue to monitor the US PsA market on a
quarterly basis through its RealTime Dynamix™ service.
Launch tracking of Bimzelx will commence following approval and
will continue for the first eighteen months of availability through
the Launch Dynamix™ service.
RealTime Dynamix™ is an independent service providing
strategic guidance through quarterly or semiannual reports, which
include market trending and a fresh infusion of event-driven and
variable content with each wave. The reports provide an unbiased
view of the competitive landscape within rapidly evolving specialty
markets, fueled by robust HCP primary research and our in-house
team of experts.
Launch Dynamix™ is an independent service providing
monthly benchmarking of newly launched products for the first
eighteen months of commercial availability, augmented by a
quarterly deep dive into promotional activity, barriers to uptake,
and patient types gravitating to the launch brand.
About Spherix Global Insights
Spherix Global Insights is a leading provider of market
research, business intelligence and advisory services to the global
life sciences industry. The company’s unique service offerings are
powered by deep therapeutic knowledge, the Spherix Network
specialty physician panel, and commercially relevant analyses to
enable strategic decision-making by our valued customers.
A trusted advisor and industry thought leader, Spherix Global
Insights provides specialized market expertise in six (6) focused
therapeutic areas including: dermatology, gastroenterology,
nephrology, neurology, rheumatology, and ophthalmology.
To learn more about Spherix Global Insights,
visit spherixglobalinsights.com or connect
through LinkedIn.
For more details on Spherix’s primary market research reports
and interactive dashboard offerings, visit or register
here: https://clientportal.spherixglobalinsights.com
NOTICE: All company, brand or product names in this press
release are trademarks of their respective holders. The findings
and opinions expressed within are based on Spherix Global Insight’s
analysis and do not imply a relationship with or endorse.
Maxine Yarnall, Rheumatology Franchise Head
Spherix Global Insights
4848794284
maxine.yarnall@spherixglobalinsights.com